

Kazuhiko Nakagawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7796081/publications.pdf>

Version: 2024-02-01

166
papers

24,228
citations

44444

50
h-index

8627

151
g-index

168
all docs

168
docs citations

168
times ranked

18146
citing authors

#	ARTICLE	IF	CITATIONS
1	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2010, 11, 121-128.	5.1	3,794
2	Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 2385-2394.	13.9	3,181
3	Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 2237-2246.	0.8	2,822
4	First-Line Crizotinib versus Chemotherapy in <i>ALK</i> -Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 2167-2177.	13.9	2,808
5	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1454-1466.	5.1	877
6	Alectinib versus crizotinib in patients with <i>ALK</i> -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2017, 390, 29-39.	6.3	753
7	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1236-1244.	5.1	678
8	CH5424802 (RO5424802) for patients with <i>ALK</i> -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1&2 study. <i>Lancet Oncology</i> , The, 2013, 14, 590-598.	5.1	555
9	Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. <i>Science Translational Medicine</i> , 2011, 3, 99ra86.	5.8	543
10	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated <i>EGFR</i> -Mutated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3290-3297.	0.8	515
11	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	3.4	446
12	Interstitial Lung Disease in Japanese Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1348-1357.	2.5	428
13	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	5.1	418
14	Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 241-251.	13.9	393
15	Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and <i>EGFR</i> -Activating Mutations. <i>Journal of Clinical Oncology</i> , 2018, 36, 2244-2250.	0.8	361
16	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 990-998.	5.1	353
17	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , 2020, 147, 2190-2198.	2.3	288
18	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	196

#	ARTICLE	IF	CITATIONS
19	Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). <i>Clinical Cancer Research</i> , 2019, 25, 5485-5492.	3.2	191
20	Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5240-5246.	0.8	161
21	Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 88, 74-79.	0.9	157
22	Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 205-215.	0.5	149
23	Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2037-2046.	3.2	142
24	Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. <i>Journal of Clinical Oncology</i> , 2016, 34, 3248-3257.	0.8	130
25	MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1624-1631.	0.5	122
26	First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naïve EGFR Mutation-Positive Non-Small Cell Lung Cancer?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 146.	1.8	118
27	Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L. <i>Journal of Clinical Oncology</i> , 2015, 33, 575-581.	0.8	109
28	Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. <i>JAMA Oncology</i> , 2021, 7, 386.	3.4	108
29	Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 29-36.	0.6	101
30	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 195-199.	0.9	100
31	Targeting MET Amplification as a New Oncogenic Driver. <i>Cancers</i> , 2014, 6, 1540-1552.	1.7	96
32	Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. <i>Journal of Clinical Oncology</i> , 2019, 37, 4079-4079.	0.8	94
33	Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2825-2833.	1.9	91
34	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. <i>Journal of Clinical Oncology</i> , 2020, 38, 9504-9504.	0.8	91
35	A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. <i>Lung Cancer</i> , 2016, 99, 186-193.	0.9	88
36	Combination therapy with PD-1 or PD-L1 inhibitors for cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 818-830.	1.0	86

#	ARTICLE	IF	CITATIONS
37	<i>MET</i> amplification as a potential therapeutic target in gastric cancer. <i>Oncotarget</i> , 2013, 4, 9-17.	0.8	82
38	Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for <i>MET</i> Amplification. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1557-1564.	1.9	75
39	Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1439-1445.	0.5	73
40	Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Nonâ€“Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR). <i>Journal of Thoracic Oncology</i> , 2012, 7, 1296-1303.	0.5	73
41	Final safety and efficacy of erlotinib in the phase 4 <scp>POLARSTAR</scp> surveillance study of 10Â708 Japanese patients with nonâ€“smallâ€“cell lung cancer. <i>Cancer Science</i> , 2014, 105, 1584-1590.	1.7	67
42	Phase III Study Comparing Amrubicin Plus Cisplatin With Irinotecan Plus Cisplatin in the Treatment of Extensive-Disease Small-Cell Lung Cancer: JCOG 0509. <i>Journal of Clinical Oncology</i> , 2014, 32, 1262-1268.	0.8	66
43	Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Nonâ€“Small-Cell Lung Cancer: AF-001JP. <i>Journal of Clinical Oncology</i> , 2017, 35, 1515-1521.	0.8	63
44	Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. <i>Lung Cancer</i> , 2018, 117, 14-19.	0.9	63
45	Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 121, 37-40.	0.9	62
46	The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. <i>Oncotarget</i> , 2014, 5, 11847-11856.	0.8	61
47	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-III A Nonâ€“Small-Cell Lung Cancer With <i>EGFR</i> Mutation (IMPACT). <i>Journal of Clinical Oncology</i> , 2022, 40, 231-241.	0.8	61
48	Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. <i>International Journal of Clinical Oncology</i> , 2016, 21, 1-12.	1.0	58
49	Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. <i>Drugs</i> , 2021, 81, 257-266.	4.9	57
50	Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 ÅJapan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1-17.	1.0	56
51	Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 462-467.	0.6	54
52	The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 33602-33611.	0.8	53
53	Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 452-463.	0.5	51
54	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, e196828.	3.4	48

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 613-621.	5.2	44
56	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. <i>Journal of Clinical Investigation</i> , 2019, 130, 374-388.	3.9	43
57	KRAS Inhibitor Resistance in <i>MET</i> -Amplified <i>KRAS</i> G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 5697-5707.	3.2	42
58	KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 1012-1020.	1.7	40
59	Phase I and Pharmacologic Study of Docetaxel and Irinotecan in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2996-3003.	0.8	38
60	Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2013, 31, 1275-1282.	1.2	38
61	Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405). <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 664-668.	0.6	38
62	Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 88, 275-281.	0.9	36
63	Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 346-352.	0.5	35
64	Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (Wrest) Trial. <i>Cancer</i> , 2016, 122, 1050-1059.	2.0	35
65	A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). <i>Clinical Cancer Research</i> , 2022, 28, 893-902.	3.2	35
66	A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. <i>Breast</i> , 2018, 40, 67-75.	0.9	34
67	HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 390-403.	3.2	34
68	A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. <i>British Journal of Cancer</i> , 2018, 119, 675-682.	2.9	32
69	Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. <i>Oncotarget</i> , 2014, 5, 2293-2304.	0.8	32
70	FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. <i>Cancer Science</i> , 2016, 107, 1667-1676.	1.7	31
71	Mutational activation of the epidermal growth factor receptor downregulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 52-60.	1.7	31
72	Real-world data on NGS using the OncoPrint DxTT for detecting genetic alterations in non-small cell lung cancer: WJOG13019L. <i>Cancer Science</i> , 2022, 113, 221-228.	1.7	31

#	ARTICLE	IF	CITATIONS
73	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). <i>Journal of Clinical Oncology</i> , 2020, 38, 793-803.	0.8	28
74	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2795-2805.	1.1	27
75	Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 367-375.	0.6	26
76	Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251.		26
77	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 126-131.	0.9	26
78	Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 489-495.	1.1	25
79	Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2. <i>Oncotarget</i> , 2018, 9, 21132-21140.	0.8	24
80	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5258-5271.	3.2	23
81	RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFR ^m) metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9000-9000.	0.8	23
82	Efficacy and Safety of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma: A Phase I/II Study in Japanese Patients. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 339-346.	0.6	22
83	New Era for Next-Generation Sequencing in Japan. <i>Cancers</i> , 2019, 11, 742.	1.7	22
84	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). , 2022, 10, e004025.		22
85	Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 105, 1-6.	0.9	21
86	Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 1724-1738.	1.7	20
87	Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9016-9016.	0.8	20
88	Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. <i>European Journal of Cancer</i> , 2022, 171, 259-268.	1.3	19
89	Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors. <i>Japanese Journal of Clinical Oncology</i> , 2008, 39, 116-123.	0.6	18
90	A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer. <i>Medical Oncology</i> , 2016, 33, 2.	1.2	18

#	ARTICLE	IF	CITATIONS
91	Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. <i>Lung Cancer</i> , 2019, 135, 145-150.	0.9	18
92	Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). <i>Lung Cancer</i> , 2019, 131, 128-133.	0.9	18
93	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). <i>Lung Cancer</i> , 2021, 154, 176-185.	0.9	18
94	Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small cell lung cancer: East Asian subset of RELAY. <i>Cancer Science</i> , 2020, 111, 4510-4525.	1.7	17
95	Clinical activity of ASP8273 in Asian patients with non-small cell lung cancer with EGFR activating and T790M mutations. <i>Cancer Science</i> , 2018, 109, 2852-2862.	1.7	15
96	Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 618-624.	0.6	14
97	Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. <i>BMC Cancer</i> , 2020, 20, 103.	1.1	14
98	Real-world safety of nivolumab in patients with non-small cell lung cancer in Japan: Postmarketing surveillance. <i>Cancer Science</i> , 2021, 112, 4692-4701.	1.7	14
99	Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, 9092-9092.	0.8	14
100	EORTC-1416-LCG/ETOP 8-15 PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. <i>Journal of Clinical Oncology</i> , 2022, 40, 8512-8512.	0.8	14
101	A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 1058-1067.	1.2	13
102	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. <i>Clinical Lung Cancer</i> , 2017, 18, 719-723.	1.1	13
103	Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. <i>Clinical Lung Cancer</i> , 2018, 19, 213-220.e4.	1.1	13
104	Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO453805 and ONO453806 studies. <i>Cancer Medicine</i> , 2019, 8, 5183-5193.		13
105	A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. <i>Scientific Reports</i> , 2019, 9, 11340.	1.6	12
106	Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. <i>Oncogenesis</i> , 2019, 8, 54.	2.1	12
107	Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors. <i>Scientific Reports</i> , 2019, 9, 19501.	1.6	12
108	Predicting osimertinib treatment outcomes through EGFR mutant fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). <i>Molecular Oncology</i> , 2021, 15, 126-137.	2.1	12

#	ARTICLE	IF	CITATIONS
109	Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. <i>Future Oncology</i> , 2019, 15, 1481-1491.	1.1	11
110	Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , 2020, 36, 1667-1675.	0.9	11
111	NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.. <i>Journal of Clinical Oncology</i> , 2020, 38, 106-106.	0.8	11
112	Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 96-99.	1.1	10
113	ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. <i>Cancer Science</i> , 2018, 109, 2532-2538.	1.7	10
114	Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). <i>Clinical Lung Cancer</i> , 2022, 23, e257-e263.	1.1	10
115	Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis. <i>Frontiers in Oncology</i> , 2021, 11, 763468.	1.3	10
116	First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2019, 18, 100113.	0.7	9
117	Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100135.	0.6	9
118	Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9004-9004.	0.8	9
119	Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 106, 1018-1024.	0.7	8
120	Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 106-113.	0.6	8
121	Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100184.	0.6	8
122	Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9031-9031.	0.8	8
123	Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 161, 44-54.	1.3	7
124	Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). <i>Clinical Cancer Research</i> , 2022, 28, 3207-3213.	3.2	7
125	First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE024 Japan subset*. <i>Cancer Science</i> , 2021, 112, 5000-5010.	1.7	6
126	RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. <i>Drug Safety</i> , 2022, 45, 45-64.	1.4	6

#	ARTICLE	IF	CITATIONS
127	Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter. <i>Oncology Letters</i> , 2015, 9, 405-410.	0.8	5
128	A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9037-9037.	0.8	5
129	Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100171.	0.6	5
130	Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). <i>Cancer Management and Research</i> , 2021, Volume 13, 9167-9173.	0.9	5
131	Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L). <i>Lung Cancer</i> , 2022, 168, 38-45.	0.9	5
132	A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer. <i>BMC Research Notes</i> , 2015, 8, 100.	0.6	4
133	Prognostic value of Lung Cancer Subscale in older patients with advanced non-small cell lung cancer: An integrated analysis of JCOG0207 and JCOG0803/WJOG4307L (JCOG1414A). <i>Journal of Geriatric Oncology</i> , 2018, 9, 583-588.	0.5	4
134	Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. <i>International Journal of Clinical Oncology</i> , 2019, 24, 485-493.	1.0	4
135	Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100178.	0.6	4
136	RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 137-148.	1.1	4
137	Current status and future perspectives of cooperative study groups for lung cancer in Japan. <i>Respiratory Investigation</i> , 2014, 52, 339-347.	0.9	3
138	Sterilized talc pleurodesis for malignant pleural effusions: a Phase II study for investigational new drug application in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 376-381.	0.6	3
139	An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 685-694.	1.1	3
140	Severe Immune-Related Hepatitis Treated With Plasma Exchange. <i>Journal of Thoracic Oncology</i> , 2020, 15, e39-e42.	0.5	3
141	Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9042-9042.	0.8	3
142	A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9003-9003.	0.8	3
143	A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9125-TPS9125.	0.8	3
144	Two cases of portal-systemic shunts demonstrated by portal venography performed by operative cannulation of ileocolic vein.. <i>Japanese Journal of Medicine</i> , 1983, 22, 31-36.	0.1	2

#	ARTICLE	IF	CITATIONS
145	Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?. <i>Translational Lung Cancer Research</i> , 2020, 9, 1617-1622.	1.3	2
146	Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model. <i>Journal of Clinical Medicine</i> , 2020, 9, 4050.	1.0	2
147	The expression level of HER3 ligand heregulin mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19082-e19082.	0.8	2
148	RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9564-9564.	0.8	2
149	Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8557-8557.	0.8	2
150	Clinical development of EGFR-tyrosine kinase inhibitors in Japan. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 33-37.	1.1	1
151	Phase I/ II Study of Cisplatin plus Nabâ€Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Nonâ€Small Cell Lung Cancer. <i>Oncologist</i> , 2021, 26, 19.	1.9	1
152	Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population. <i>Future Oncology</i> , 2021, 17, 103-115.	1.1	1
153	Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. <i>Cancer Biomarkers</i> , 2021, 31, 119-126.	0.8	1
154	Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 685-692.	0.6	1
155	NGSCUP: Phase II trial of site-specific treatment based on gene expression and mutation profiling by next generation sequencing (NGS) for patients (pts) with cancer of unknown primary site (CUP).. <i>Journal of Clinical Oncology</i> , 2020, 38, e15577-e15577.	0.8	1
156	RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9527-9527.	0.8	1
157	Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study. <i>Drugs in R and D</i> , 2021, 21, 65-78.	1.1	1
158	RELAY+: Exploratory Study of Ramucirumab Plusâ€Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100303.	0.6	1
159	Perspectives in drug development for cancer therapy in Asia. <i>Chinese Clinical Oncology</i> , 2012, 1, 17.	0.4	1
160	The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21177-e21177.	0.8	1
161	The patientâ€™s perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050. <i>Future Oncology</i> , 2021, 17, 783-794.	1.1	0
162	Challenges in lung cancer multidisciplinary collaboration experienced by specialists in four countries.. <i>Journal of Clinical Oncology</i> , 2021, 39, e23002-e23002.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Phase I dose finding study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, alone or in combination with paclitaxel in Japanese patients.. Journal of Clinical Oncology, 2013, 31, e13501-e13501.	0.8	0
164	The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).. Journal of Clinical Oncology, 2019, 37, 9038-9038.	0.8	0
165	Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L).. Journal of Clinical Oncology, 2019, 37, e20531-e20531.	0.8	0
166	Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).. Journal of Clinical Oncology, 2022, 40, e21175-e21175.	0.8	0